Outlook Therapeutics Appoints Bob Jahr as CEO to Lead Commercial Expansion

Iselin, NJ, July 1, 2025 (GlobeNewswire) -- Outlook Therapeutics has appointed biopharma veteran Bob Jahr as Chief Executive Officer, as the company prepares for commercial growth and potential FDA approval of its bevacizumab treatment for retinal diseases. Jahr, who also joins the Board of Directors, brings over two decades of experience leading commercial operations across multiple therapeutic areas and billion-dollar franchises. Interim CEO and CFO Lawrence Kenyon will continue in his CFO role and remain on the Board. With its European launch underway, Outlook Therapeutics aims to leverage Jahr’s leadership to scale operations and deliver stakeholder value.

Read full article here.